
KRRO Stock Forecast & Price Target
KRRO Analyst Ratings
Bulls say
Korro Bio Inc has recently made significant advancements in its development of KRRO-121, a liver-targeted RNA editing drug, which has demonstrated the ability to stabilize glutamine synthetase and improve ammonia clearance, a critical factor given the unmet needs in treating urea cycle disorders and hepatic encephalopathy. The strong preclinical data from mouse and non-human primate studies suggest robust safety and efficacy, coupled with a potential market opportunity of approximately $1.5 billion to $2.0 billion for these conditions. With KRRO-121's Investigational New Drug (IND) filing anticipated in the second half of 2026, Korro Bio’s strategic progress and the promising pharmacoeconomic upside create a positive outlook for its stock.
Bears say
Korro Bio has experienced significant stock selloff following disappointing results from its KRRO-110 AATD program, highlighting the ongoing concerns regarding the efficacy of its pipeline candidates. The company's risk profile is further exacerbated by potential delays in clinical trial advancements, the necessity for favorable clinical data from ongoing programs, and the threat of long-term dilution due to funding requirements. Additionally, uncertainties surrounding regulatory interpretations and possible obsolescence of its therapies due to advancements from competitors contribute to a cautious outlook on Korro Bio's financial stability and market position.
This aggregate rating is based on analysts' research of Frequency Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
KRRO Analyst Forecast & Price Prediction
Start investing in KRRO
Order type
Buy in
Order amount
Est. shares
0 shares